What Is the Prognosis for Ovarian Cancer With Ascites?

Ascites, a build-up of fluid in the belly, is common in ovarian cancer and usually means the cancer has spread within the abdomen. In many other cancers, fluid like this signals only months left. Ovarian cancer is the exception: with ascites it often still responds well to surgery and chemotherapy.¹ The fluid is a warning sign that nudges the odds, not a verdict, and some women with it live a decade or longer.²

How Much Ascites Changes Survival

Most women with ovarian cancer are diagnosed at stage 3 or 4, when fluid in the belly is often present.³ With surgery and chemotherapy, the cancer typically stays under control for a median of 16 to 22 months before it returns.⁴ In older figures, about 27% of women are alive at five years, and results have improved with newer treatments.⁵ More than a third of women develop fluid at some point, across all ovarian cancer types.⁶

On top of that baseline, the fluid adds a moderate, measurable risk. In a large trial of women starting first treatment for advanced cancer, those with fluid in the belly had about a 22% higher risk of dying over the study, after other factors were accounted for.⁷ Yet in that same trial, the fluid did not shorten the time before the cancer came back.⁸ Even in early-stage disease, fluid at diagnosis is linked to poorer survival.⁹

A 22% higher risk does not mean a 22% chance of dying. It means that across many women, deaths happened somewhat more often or sooner in the group with fluid. Individual outcomes vary widely around those averages, and your doctor can place you using your own stage and test results.

Median survival figures can mislead in a similar way. A median is the midpoint: half of women do better, often much better. Many figures also come from women treated years ago with older drugs.

Part of the link to survival also reflects the cancer rather than the fluid. Fluid usually travels with other features of advanced disease, such as more widespread tumour in the belly. The trial’s adjustment for other factors is meant to separate the fluid’s own effect, but no statistical method removes that overlap completely. The fluid is best read as one clue among several, alongside stage, cancer type and how much tumour surgery removes.

Does the Amount of Fluid Matter

It does. More fluid is linked to a higher chance of the cancer returning and a higher risk of death.¹⁰ In one study, more than 100 mL of fluid, about a third of a can of soda, was the point above which survival was shorter.¹¹

The pattern holds even after surgery removes all visible tumour. Women with a small amount of fluid did worse than those with none, and women with a large amount did worse still.¹² In that group, a large amount nearly doubled the risk of death compared with no fluid.¹³ Women with a small amount had about 30% lower risk of death than those with a large amount.¹⁴

Larger volumes usually reflect more tumour spread across the belly lining. More fluid also often comes with weight loss and low protein levels, which weaken the body.

The 100 mL figure comes from one study and describes where survival differences appeared in that group, so it is not a cutoff that applies exactly to every woman. Risk rises gradually as volume increases, and the outlook does not suddenly collapse at that line.

A CT scan or ultrasound before surgery often estimates how much fluid you have, and the surgeon usually measures the fluid removed during the operation. Your surgical report may describe it as small or large volume, sometimes in millilitres. It is reasonable to ask your team what amount was found. Bloating alone does not tell you how much fluid you have, since it also comes from the tumour, gas and bowel changes.

Why Surgery Results Matter So Much

Debulking surgery aims to remove as much tumour as possible, ideally leaving none visible. Women with fluid in the belly are less likely to have the tumour removed down to small leftovers, even at the same stage.¹⁵ In one study, tumour pieces larger than 1 cm were left behind in 39% of women with a lot of fluid, versus 18% with a little.¹⁶ The cancer stayed away for a median of 2.8 years with a small amount of fluid, versus 1.6 years with a large amount.¹⁷

Surgeons often describe the result by the size of what is left behind, with the best outcome being no visible tumour at all. That predicts survival because chemotherapy has far less cancer to deal with when only microscopic disease remains. Removing tumour can involve parts of the bowel, the belly lining or other organs, which is why this surgery is long and best done by a specialist team.

Large volumes can also come with a weakened body, which limits how extensive an operation a woman can safely have. The surgeon aims for a balance between removing as much as possible and keeping her safe through recovery.

When complete removal looks unlikely, doctors may give chemotherapy first to shrink tumours and fluid. Surgery then follows. This order is common and is not a sign of giving up. Ask your surgeon how much tumour they expect to remove and why they chose that order. After surgery, useful questions are whether any visible tumour was left behind and how large it was, how much fluid was found and whether it contained cancer cells, and what the findings mean for your chemotherapy plan.

Other Factors That Shape the Outlook

Worse survival was linked to older age, high-grade cancer, low hemoglobin, low albumin (a blood protein), and being less able to do daily activities.¹⁸ Receiving chemotherapy after the fluid was found was linked to lower death risk.¹⁹

Cancer cells in the fluid add information. When fluid tested during surgery contains cancer cells, the risk of the cancer returning is about 54% higher and the risk of death about 67% higher.²⁰ Cancerous fluid is most common with high-grade serous cancer, found in about 92% of those women in one hospital series, versus 18% with low-grade serous.²¹ In one large study, the amount of fluid mattered most for mucinous and endometrioid cancers.²²

Grade describes how abnormal the cancer cells look under the microscope, with high-grade cells tending to grow faster. High-grade serous is the most common type of ovarian cancer and the one that most often produces fluid. Low-grade cancers grow more slowly and tend to respond differently to chemotherapy, so the same fluid can carry a different meaning.

Your pathology report usually names the type, such as high-grade serous. Peritoneal washings or ascites cytology tells you whether cancer cells were in the fluid. Albumin and hemoglobin appear on routine blood tests, and improving nutrition and treating anemia are things your team can help with.

Older age was linked to worse survival, though age is partly a stand-in for other health problems and for how much treatment a woman can tolerate. Being less able to do daily activities usually reflects how unwell the cancer or fluid is making someone, and it can improve once symptoms are treated. Fitness also guides which chemotherapy and surgery options are offered, so it affects the plan as well as the odds.

Some of these factors change over time. Strength and daily function often improve once fluid is drained and treatment starts, and blood counts and protein levels can recover with treatment and good nutrition. Ask your team which of your numbers they are watching.

Treatments That Can Improve Outcomes With Ascites

The fluid is driven largely by a leak-promoting signal. Tumours release a substance called VEGF, the target of drugs such as bevacizumab, that makes blood vessels in the belly leaky, letting fluid seep out.²³ Normally the belly lining drains such fluid away, but blocked drainage channels let it collect instead.²⁴ In lab animals, blocking VEGF stopped fluid build-up completely even though tumours kept growing somewhat.²⁵ Treatments that block VEGF therefore aim at the leak itself, rather than only at shrinking the tumour.

Bevacizumab (Avastin) is a drug that blocks VEGF. In the large first-treatment trial, women with fluid gained a survival benefit from adding it.²⁶ Among women who had fluid, 44% on bevacizumab reported clearly better belly and bowel symptoms after two months, versus 4% on chemotherapy alone.²⁷

It is given through a vein, usually along with chemotherapy and often continued on its own afterwards for a period. Side effects can include high blood pressure, protein in the urine and slower wound healing, so blood pressure is checked at visits and the timing around surgery is planned carefully. It is also linked to a rare risk of a hole forming in the bowel, which is a reason it is not suited to everyone.

HIPEC, heated chemotherapy washed through the belly during surgery, may reduce the effect of heavy fluid. In one study, women with massive fluid treated with HIPEC did about as well as women with little or none, averaging around 57 months survival.²⁸ Adding it to surgery after chemotherapy has improved survival in a major trial.²⁹

Bevacizumab is widely used with first-line chemotherapy, while HIPEC is offered only at some centres and for selected patients. Mention your fluid when discussing these options. A second opinion at a specialist gynecologic cancer centre is reasonable.

When the Fluid Keeps Coming Back

Paracentesis, draining the fluid through a needle in the belly, is the usual way to relieve pressure and breathlessness.³⁰ In some women the fluid returns quickly, needing frequent repeat drainings.³¹ A drain left in place lets fluid be removed at home and can give longer relief, though it carries risks such as infection.³²

A permanent drain is usually considered when fluid keeps returning quickly and repeated needle visits become a burden. The main risks are infection and blockage of the tube, so the site needs to be kept clean and any redness, fever or leakage reported promptly.

A drainage visit is simple. A doctor numbs the skin and inserts a thin needle, often using ultrasound. Several litres can be removed over an hour or so, and relief from bloating and breathlessness is usually immediate. Mild dizziness can occur, so arrange a ride home.

Signs the fluid is coming back include a tightening waistband or rapid weight gain, feeling full after small meals, and shortness of breath when lying flat. Call your team early rather than waiting for severe discomfort.

Some drugs slow the return of fluid. In women whose cancer no longer responded to chemotherapy, bevacizumab given into the belly made the gap between drainings about four times longer.³³ In a small case series, three of four heavily treated women needed no further draining after bevacizumab.³⁴ Catumaxomab, an antibody approved in Europe for fluid in the belly, kept 22 of 23 women free of draining for up to about five weeks, though side effects like fever and nausea were common.³⁵³⁶

These studies involved women whose fluid kept coming back despite earlier treatment, a harder group than most women newly diagnosed. The bevacizumab case series was only four women, so it suggests a possibility rather than proof. Catumaxomab is approved in Europe, but availability elsewhere varies, so readers outside Europe may find it reachable only through trials.

Why Ascites Can Make Cancer Harder to Treat

The fluid is an active environment, not just water. Single cancer cells floating in it tend to die, but cells that join into small balls can survive.³⁷ Inside a clump, cells on the outside shield those in the middle, so a drug can have trouble reaching all of them. In lab tests, these clumps resisted the chemotherapy drug cisplatin up to four times better than single cells.³⁸ That may help explain why a cancer that looked controlled can come back, since clumps that survive treatment can restart growth.

The clumps can also stick to the belly lining and to organs, which may help the cancer spread and start new tumour spots.³⁹ The fluid holds immune cells that suppress the body’s attack on the tumour,⁴⁰ and it carries growth-promoting chemical signals that cancer cells use to survive.

These findings come mostly from lab and animal studies, not patients. They do not mean chemotherapy will fail for you. They help explain why treating the fluid and tumour together makes sense, and clinical trials testing these ideas may be an option to ask about.